SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Jankowski Jess – ‘4’ for 11/18/22 re: Nanophase Technologies Corp.

On:  Tuesday, 11/22/22, at 9:00pm ET   ·   For:  11/18/22   ·   As:  Director and Officer   ·   Accession #:  1209191-22-58550   ·   File #:  0-22333

Previous ‘4’:  ‘4’ on 11/17/22 for 11/15/22   ·   Next:  ‘4’ on 11/28/22 for 11/23/22   ·   Latest:  ‘4’ on 2/13/24 for 2/9/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/22/22  Jankowski Jess                    4          Dir.,Off.   1:20K  Nanophase Technologies Corp.      DONNELLEY FIN… File16/FA

Statement of Changes in Beneficial Ownership of Securities by an Insider   —   Form 4   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 4           Form 4 Submission -- doc4.xml/3.6                   HTML     20K 




        

This ‘4’ Document is an XML Data File that may be rendered in various formats:

  Form 4    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 

 
SEC Info rendering:  Form 4 Submission
 
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
JANKOWSKI JESS

(Last)(First)(Middle)
1319 MARQUETTE DRIVE

(Street)
ROMEOVILLEIL60446

(City)(State)(Zip)
2. Issuer Name and Ticker or Trading Symbol
NANOPHASE TECHNOLOGIES Corp [ NANX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector 10% Owner
XOfficer (give title below) Other (specify below)
President, CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/18/22
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock 1,000ISpouse's IRA
Common Stock 59,000D
Common Stock 11/18/22 (1)M 10,000A$0.415 (1)69,000D
Common Stock 11/18/22 (2)S 10,000D$1.4 (3)59,000D
Common Stock 11/21/22 (1)M 2,600A$0.41561,600D
Common Stock 11/21/22 (2)S 2,600D$1.38 (4)59,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Common Stock (right to purchase)$0.415 11/18/22 (5)M 10,000 2/14/14 2/14/23Common Stock44,226$0.41534,226D
Common Stock (right to purchase)$0.415 11/21/22 (5)M 2,600 2/14/14 2/14/23Common Stock34,226$0.41531,626D
Common Stock (right to purchase)$0.52 2/13/15 (6) 2/13/24Common Stock90,000 90,000D
Common Stock (right to purchase)$0.44 2/18/16 (7) 2/18/25Common Stock81,000 81,000D
Common Stock (right to purchase)$0.42 2/23/17 (7) 2/23/26Common Stock69,000 69,000D
Common Stock (right to purchase)$0.68 2/21/18 (7) 2/21/27Common Stock81,000 81,000D
Common Stock (right to purchase)$0.82 5/23/19 (8) 5/23/28Common Stock90,000 90,000D
Common Stock (right to purchase)$0.51 5/22/20 (6) 5/22/29Common Stock16,500 16,500D
Common Stock (right to purchase)$0.45 6/18/21 (6) 6/18/27Common Stock90,000 90,000D
Common Stock (right to purchase)$4.17 12/28/22 (6) 12/28/28Common Stock90,000 90,000D
Explanation of Responses:
(1)  These stock options are set to expire on 2/14/23. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
(2)  If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc.
(3)  The price reported is a weighted average price. These shares were sold through multiple transactions, eleven in all, at prices ranging from $1.37 to $1.45.
(4)  The price reported is a weighted average price. These shares were sold through multiple transactions, five in all, at prices ranging from $1.36 to $1.40.
(5)  These stock options are set to expire on 2/14/23. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
(6)  Subject to certain restrictions, beginning on this date, options vest in three equal installments.
(7)  Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments.
(8)  Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
Remarks:
Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having shares from this grant sold, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. The maturity of these rights cannot be extended beyond the IRS statutory limit of ten years.
Jess A. Jankowski 11/22/22
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
____________
Transaction Codes:
    M    Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
    S    Open market or private sale of non-derivative or derivative security.

Top
Filing Submission 0001209191-22-058550   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 20, 3:33:29.1am ET